BACKGROUND: Streptococcus pneumoniae is a major cause of morbidity and mortality in young children in the developing world. The recent development of pneumococcal polysaccharide/protein conjugate vaccines may make possible prevention of this infection. However, little is known about the epidemiology of invasive pneumococcal disease in children in the developing world. OBJECTIVES: To determine the incidence and epidemiologic features of invasive pneumococcal disease in children resident in a semiurban area of The Gambia. METHOD: The study was part of a large trial of an Haemophilus influenzae type b vaccine that recruited 42 848 children at the age of 2 months during the period March, 1993, to October, 1995. Follow-up of study children continued until December 31, 1995; therefore the first children to enter the trial were followed for 2.5 years and the last for just a few months. During the period of surveillance, 2256 children were investigated for possible invasive pneumococcal disease when they presented to a hospital or health center. RESULTS: We detected 110 cases of pneumococcal disease. Pneumonia was the most common form of invasive pneumococcal disease observed (75.5% of patients). The incidence of pneumococcal disease was 224 [95% confidence interval (CI) 171, 277] per 100,000 child years among children ages 2 to 11 months, 139 (95% CI 93, 184) per 100,000 among children ages 12 to 23 months and 82 (95% CI 21, 143) per 100,000 among children ages 24 to 35 months. Pneumococci of serogroups 14, 6, 5, 23, 19, 46 and 2 were isolated most frequently. Susceptibility to pneumococcal disease was not increased significantly among Haemophilus influenzae type b-vaccinated children. CONCLUSIONS: The pneumococcus is a major cause of bacterial infection in The Gambia. A proposed nine-valent pneumococcal conjugate vaccine for developing countries containing conjugates of serogroups 1, 4, 5, 6, 9, 14, 18, 19 and 23 would cover 74% of cases of invasive pneumococcal disease in children resident in the Western Region of The Gambia.
BACKGROUND:Streptococcus pneumoniae is a major cause of morbidity and mortality in young children in the developing world. The recent development of pneumococcal polysaccharide/protein conjugate vaccines may make possible prevention of this infection. However, little is known about the epidemiology of invasive pneumococcal disease in children in the developing world. OBJECTIVES: To determine the incidence and epidemiologic features of invasive pneumococcal disease in children resident in a semiurban area of The Gambia. METHOD: The study was part of a large trial of an Haemophilus influenzae type b vaccine that recruited 42 848 children at the age of 2 months during the period March, 1993, to October, 1995. Follow-up of study children continued until December 31, 1995; therefore the first children to enter the trial were followed for 2.5 years and the last for just a few months. During the period of surveillance, 2256 children were investigated for possible invasive pneumococcal disease when they presented to a hospital or health center. RESULTS: We detected 110 cases of pneumococcal disease. Pneumonia was the most common form of invasive pneumococcal disease observed (75.5% of patients). The incidence of pneumococcal disease was 224 [95% confidence interval (CI) 171, 277] per 100,000 child years among children ages 2 to 11 months, 139 (95% CI 93, 184) per 100,000 among children ages 12 to 23 months and 82 (95% CI 21, 143) per 100,000 among children ages 24 to 35 months. Pneumococci of serogroups 14, 6, 5, 23, 19, 46 and 2 were isolated most frequently. Susceptibility to pneumococcal disease was not increased significantly among Haemophilus influenzae type b-vaccinated children. CONCLUSIONS: The pneumococcus is a major cause of bacterial infection in The Gambia. A proposed nine-valent pneumococcal conjugate vaccine for developing countries containing conjugates of serogroups 1, 4, 5, 6, 9, 14, 18, 19 and 23 would cover 74% of cases of invasive pneumococcal disease in children resident in the Western Region of The Gambia.
Entities:
Keywords:
Africa; Africa South Of The Sahara; Age Factors; Bacterial And Fungal Diseases; Child; Demographic Factors; Developing Countries; Diseases; English Speaking Africa; Epidemiology; Examinations And Diagnoses; Gambia; Health; Incidence; Infections; Laboratory Examinations And Diagnoses; Measurement; Nonmetropolitan Population; Population; Population Characteristics; Public Health; Research Methodology; Research Report; Respiratory Infections; Retrospective Studies; Studies; Western Africa; Youth
Authors: F Shackley; K Knox; J B Morris; D Crook; D Griffiths; R Mayon-White; R George; L Willocks; E Moxon Journal: Arch Dis Child Date: 2000-09 Impact factor: 3.791
Authors: Grant Mackenzie; Serign J Ceesay; Philip C Hill; Michael Walther; Kalifa A Bojang; Judith Satoguina; Godwin Enwere; Umberto D'Alessandro; Debasish Saha; Usman N A Ikumapayi; Tim O'Dempsey; David C W Mabey; Tumani Corrah; David J Conway; Richard A Adegbola; Brian M Greenwood Journal: PLoS One Date: 2010-05-11 Impact factor: 3.240
Authors: Anna Roca; Philip C Hill; John Townend; Uzo Egere; Martin Antonio; Abdoulie Bojang; Abiodun Akisanya; Teresa Litchfield; David E Nsekpong; Claire Oluwalana; Stephen R C Howie; Brian Greenwood; Richard A Adegbola Journal: PLoS Med Date: 2011-10-18 Impact factor: 11.069
Authors: Brenda A Kwambana; Michael R Barer; Christian Bottomley; Richard A Adegbola; Martin Antonio Journal: BMC Infect Dis Date: 2011-06-20 Impact factor: 3.090
Authors: Martin O C Ota; Anna Roca; Christian Bottomley; Philip C Hill; Uzochukwu Egere; Brian Greenwood; Richard A Adegbola Journal: PLoS One Date: 2012-08-14 Impact factor: 3.240